OMNIPAQUE 9 Drug Patent Profile
When do Omnipaque 9 patents expire, and what generic alternatives are available?
Omnipaque 9 is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in OMNIPAQUE 9 is iohexol. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the iohexol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Omnipaque 9
A generic version of OMNIPAQUE 9 was approved as iohexol by AMNEAL on November 13th, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for OMNIPAQUE 9?
- What are the global sales for OMNIPAQUE 9?
- What is Average Wholesale Price for OMNIPAQUE 9?
Summary for OMNIPAQUE 9
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 94 |
| Clinical Trials: | 26 |
| Patent Applications: | 4,368 |
| DailyMed Link: | OMNIPAQUE 9 at DailyMed |
Recent Clinical Trials for OMNIPAQUE 9
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, San Diego | PHASE2 |
| Breakthrough T1D | PHASE2 |
| Fédération des médecins résidents du Québec | Phase 4 |
Pharmacology for OMNIPAQUE 9
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for OMNIPAQUE 9
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNIPAQUE 9 | iohexol | SOLUTION;ORAL | 018956-008 | Apr 17, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OMNIPAQUE 9
See the table below for patents covering OMNIPAQUE 9 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 318134 | ⤷ Start Trial | |
| Belgium | 752574 | ⤷ Start Trial | |
| Brazil | 7020080 | ⤷ Start Trial | |
| Canada | 935153 | 2,4,6-TRIIODOBENZOYL AMINES USED AS X-RAY CONTRAST AGENTS | ⤷ Start Trial |
| Switzerland | 544551 | Neue Röntgenkontrastmittel | ⤷ Start Trial |
| Germany | 2031724 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch